Financial Results for the Third Quarter of
Fiscal Year Ending March 31, 2023 (FY2022)

from the beginning

Financial Results for the ThirdQuarter of Fiscal Year Ending March 31, 2023 (FY2022)

• Safe Harbor for Forward-Looking Statements and Use of Document

• Highlights

• P&L Results

• Operating Profit Variance Analysis (Q3)

• Operating Profit Variance Analysis (Q3 YTD)

• Revenue by Region

• C&V: 6% growth excluding FX. China grew high-single digit Segment profit improved both YoY and QoQ due to FX and expense control

• TMCS: HCS: Japan demand showing signs of recovery PS: New products added, rapid growth Pricing action in Japan to offset macro environment impact

• TBCT: Blood centers outside Japan strong, maintaining double-digit growth excluding FX Update for plasma innovation; IDE approval for nomogram ver.2 last weekend

• Guidance Revision

• Dividend Guidance Revision

• New Measures to Raise Corporate Value

Reference

• Product Pipeline and Major Topics

• Revenue by Segment and Region

• Quarterly Trend of Revenue and Operating Profit

• P&L (QoQ)

• SG&A (QoQ)

• SG&A (YoY)

• Adjusted Operating Profit amount

• CAPEX, Depreciation and R&D Expenses

• Cash Flows (Q3 YTD)

• Cash Flows (Q3)

• FY22 FX Impact Breakdown (Flow, Stock)

• Foreign Exchange Sensitivity

@